Case of parvovirus B19 infection and immunodeficiency in the patient with Gilbert syndrome

A case of long-term persistence of parvovirus B19 is described for the first time in a patient with Gilbert's syndrome against the background of immunodeficiency with predominance of infectious symptoms (chronic herpesvirus infection). Previously, the patient (male, 48 years old) was diagnosed...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: A. Yu. Antipova, V. G. Drobyshevskaia, I. V. Khamitova
Formato: article
Lenguaje:RU
Publicado: SPb RAACI 2021
Materias:
dna
inf
Acceso en línea:https://doaj.org/article/a730696523a04a1bab11978ea045b142
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:a730696523a04a1bab11978ea045b142
record_format dspace
spelling oai:doaj.org-article:a730696523a04a1bab11978ea045b1422021-11-18T08:03:51ZCase of parvovirus B19 infection and immunodeficiency in the patient with Gilbert syndrome1563-06252313-741X10.15789/1563-0625-COP-2325https://doaj.org/article/a730696523a04a1bab11978ea045b1422021-11-01T00:00:00Zhttps://www.mimmun.ru/mimmun/article/view/2325https://doaj.org/toc/1563-0625https://doaj.org/toc/2313-741XA case of long-term persistence of parvovirus B19 is described for the first time in a patient with Gilbert's syndrome against the background of immunodeficiency with predominance of infectious symptoms (chronic herpesvirus infection). Previously, the patient (male, 48 years old) was diagnosed with Gilbert's syndrome, chronic rhinosinusopharyngitis, and chronic herpesvirus infection. In July 2017, parvovirus B19 DNA was detected in blood. No clinical manifestations of infectious erythema were noted. The patient was admitted to the medical center of St. Petersburg Pasteur Institute. His blood samples obtained under informed consent were examined at the medical center in Central Clinical and Diagnostic Laboratory of St. Petersburg Pasteur Institute in January and June 2018 and in November 2019. ELISA test systems “Anti-Parvovirus B19 ELISA (IgM)” and “Anti-Parvovirus B19 ELISA (IgG)” (Euroimmune, Germany), as well PCR reagent kit “AmpliSens Parvovirus B19-FL” (FSB Central Research Institute of Epidemiology of Rospotrebnadzor, Russia) were used for specific diagnostics. Interferon status was determined by the induced production of IFN types I, II and circulating (serum) interferons. Moreover, we considered the laboratory data obtained earlier at different medical facilities of St. Petersburg. IgM class antibodies to the parvovirus B19 were not detected in the blood samples obtained in 2018. IgG antibody titer was 96 IU/ml and 264 IU /ml, respectively. Parvovirus B19 DNA was isolated from blood plasma, but the viral load was less than 720 IU of PVB19 DNA/ml (1.5 x 102 and 1.9 x 102 copies of DNA/ml, respectively). Clinical blood analysis, showed only minor (no more than 7%) deviations from the reference values, increased hemoglobin saturation of red blood cells (RBC), a decreased width of RBC distribution curve, and relative lymphocytosis. A deficiency of various interferon types was revealed: IFNγ level was 80 IU/ml in both samples, IFNα, IFNβ amounts varied from 80 to 160 IU/ml, respectively. The period of parvovirus B19 DNA persistence in blood was 11 months in presence of immunodeficiency. The patient was administered drugs of the interferon group. Parvovirus B19 DNA was not detected in clinical samples of November 2019; IFNα, IFNβ and IFNγ values were 160 IU/ml. We have detected recovery of lymphoid cell ratio, increase in their number, and improved indexes of interferon status.A. Yu. AntipovaV. G. DrobyshevskaiaI. V. KhamitovaSPb RAACIarticlegilbert's syndromeparvovirus b19herpesdnaimmunityinfinfectionImmunologic diseases. AllergyRC581-607RUMedicinskaâ Immunologiâ, Vol 23, Iss 5, Pp 1177-1182 (2021)
institution DOAJ
collection DOAJ
language RU
topic gilbert's syndrome
parvovirus b19
herpes
dna
immunity
inf
infection
Immunologic diseases. Allergy
RC581-607
spellingShingle gilbert's syndrome
parvovirus b19
herpes
dna
immunity
inf
infection
Immunologic diseases. Allergy
RC581-607
A. Yu. Antipova
V. G. Drobyshevskaia
I. V. Khamitova
Case of parvovirus B19 infection and immunodeficiency in the patient with Gilbert syndrome
description A case of long-term persistence of parvovirus B19 is described for the first time in a patient with Gilbert's syndrome against the background of immunodeficiency with predominance of infectious symptoms (chronic herpesvirus infection). Previously, the patient (male, 48 years old) was diagnosed with Gilbert's syndrome, chronic rhinosinusopharyngitis, and chronic herpesvirus infection. In July 2017, parvovirus B19 DNA was detected in blood. No clinical manifestations of infectious erythema were noted. The patient was admitted to the medical center of St. Petersburg Pasteur Institute. His blood samples obtained under informed consent were examined at the medical center in Central Clinical and Diagnostic Laboratory of St. Petersburg Pasteur Institute in January and June 2018 and in November 2019. ELISA test systems “Anti-Parvovirus B19 ELISA (IgM)” and “Anti-Parvovirus B19 ELISA (IgG)” (Euroimmune, Germany), as well PCR reagent kit “AmpliSens Parvovirus B19-FL” (FSB Central Research Institute of Epidemiology of Rospotrebnadzor, Russia) were used for specific diagnostics. Interferon status was determined by the induced production of IFN types I, II and circulating (serum) interferons. Moreover, we considered the laboratory data obtained earlier at different medical facilities of St. Petersburg. IgM class antibodies to the parvovirus B19 were not detected in the blood samples obtained in 2018. IgG antibody titer was 96 IU/ml and 264 IU /ml, respectively. Parvovirus B19 DNA was isolated from blood plasma, but the viral load was less than 720 IU of PVB19 DNA/ml (1.5 x 102 and 1.9 x 102 copies of DNA/ml, respectively). Clinical blood analysis, showed only minor (no more than 7%) deviations from the reference values, increased hemoglobin saturation of red blood cells (RBC), a decreased width of RBC distribution curve, and relative lymphocytosis. A deficiency of various interferon types was revealed: IFNγ level was 80 IU/ml in both samples, IFNα, IFNβ amounts varied from 80 to 160 IU/ml, respectively. The period of parvovirus B19 DNA persistence in blood was 11 months in presence of immunodeficiency. The patient was administered drugs of the interferon group. Parvovirus B19 DNA was not detected in clinical samples of November 2019; IFNα, IFNβ and IFNγ values were 160 IU/ml. We have detected recovery of lymphoid cell ratio, increase in their number, and improved indexes of interferon status.
format article
author A. Yu. Antipova
V. G. Drobyshevskaia
I. V. Khamitova
author_facet A. Yu. Antipova
V. G. Drobyshevskaia
I. V. Khamitova
author_sort A. Yu. Antipova
title Case of parvovirus B19 infection and immunodeficiency in the patient with Gilbert syndrome
title_short Case of parvovirus B19 infection and immunodeficiency in the patient with Gilbert syndrome
title_full Case of parvovirus B19 infection and immunodeficiency in the patient with Gilbert syndrome
title_fullStr Case of parvovirus B19 infection and immunodeficiency in the patient with Gilbert syndrome
title_full_unstemmed Case of parvovirus B19 infection and immunodeficiency in the patient with Gilbert syndrome
title_sort case of parvovirus b19 infection and immunodeficiency in the patient with gilbert syndrome
publisher SPb RAACI
publishDate 2021
url https://doaj.org/article/a730696523a04a1bab11978ea045b142
work_keys_str_mv AT ayuantipova caseofparvovirusb19infectionandimmunodeficiencyinthepatientwithgilbertsyndrome
AT vgdrobyshevskaia caseofparvovirusb19infectionandimmunodeficiencyinthepatientwithgilbertsyndrome
AT ivkhamitova caseofparvovirusb19infectionandimmunodeficiencyinthepatientwithgilbertsyndrome
_version_ 1718422305588117504